Zhengye Biotechnology Holding Limited cash flow statement ZYBT
In fiscal 2025, which ended Dec 31, 2025, Zhengye Biotechnology Holding Limited generated $1.9 million of cash from operations, down 66.0% from the year before. It spent $144,000 on capital expenditures. That left free cash flow of $1.8 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|
| Operating | ||
| Depreciation and amortization |
4
+11.8%
|
3
|
| Operating cash flow |
2
-66.0%
|
6
|
| Investing | ||
| Capital expenditures |
0
-92.3%
|
2
|
| Investing cash flow |
-2
+52.3%
|
-4
|
| Financing | ||
| Dividends paid |
—
|
2
|
| Financing cash flow |
5
+252.5%
|
-3
|
| Change in cash | ||
| Effect of exchange rate |
-0
-963.6%
|
0
|
| Net change in cash |
5
|
—
|
| Free cash flow |
2
-53.0%
|
4
|
| Per share | ||
| Free cash flow per share |
0.04
-54.7%
|
0.08
|
| Shareholder returns | ||
| Returned to shareholders |
—
|
2
|
| Share of free cash flow |
—
|
58.35%
|
| Ratios | ||
| Free cash flow margin |
10.62%
|
14.74%
|
| Capital expenditures to revenue |
0.87%
|
7.29%
|
| Cash conversion |
—
|
3.63x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYBT (Nasdaq)
- Incorporated in
- China
- Headquarters
- Jilin
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1975641
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.